The Alzheimer's disease therapeutics market share is forecast to reach USD 3.99 billion, after growing at a CAGR of 8.76% during 2023-2027. The availability, research, and development of novel biomarkers is analyzed to boost the addictions therapeutics market growth. Moreover, the emergence of regenerative therapies is the major trend enhancing the overall market demand for Alzheimer's disease therapeutics during the forecast period.
Get a snapshot of the Alzheimer's disease therapeutics market analysis: Unlock the Sample Report
Browse Technavio's 138-page report and in-depth TOC on "Alzheimer's Disease Therapeutics Market by drug class (cholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, and other drug class) and geography (North America, Europe, Asia, and Rest of World (ROW)).
View detailed Table of Contents Here: https://www.technavio.com/report/alzheimers-disease-therapeutics-market-industry-size-analysis
Drug Class:
Cholinesterase inhibitors: The AD therapeutics market share growth by the cholinesterase inhibitors segment will be significant during the forecast period. One of the possible therapeutic strategies is to increase the cholinergic levels in the brain by inhibiting the biological activity of acetylcholinesterase.
N-methyl-D-aspartate receptor antagonists
Other drug class
Geography:
North America: 37% of the market's growth will originate from North America. The increasing funding for the development of novel therapeutics to treat Alzheimer's disease will facilitate the AD therapeutics market growth in North America over the forecast period.
Europe
Asia,
Rest of World (ROW)
The Alzheimer's disease therapeutics market size will witness a YOY Growth Rate of 8.41% in 2023.
The high cost of therapeutics development will be a major challenge for the Alzheimer's disease therapeutics market during the forecast period.
Major key Alzheimer's disease therapeutics market players include: AB Science SA, AbbVie Inc., AgeneBio Inc., Aurobindo Pharma Ltd., Biogen Inc., Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lupin Ltd., Neuronascent Inc., Novartis AG, Shanghai Green Valley Pharmaceuticals Co. Ltd., Spinogenix Inc., T3D Therapeutics Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Vivoryon Therapeutics AG
The report illustrates the lifecycle of the market, focusing on the adoption rates of the major regions such as the North America, Europe, Asia, and Rest of World (ROW).
Download the PDF sample report for highlights on the market size, growth momentum, regional growth opportunities, vendor analysis, and other factors influencing the market growth.
Precise market size estimation during the forecast period 2022-2026.
CAGR of the Alzheimer's disease therapeutics market forecast during 2022-2026.
Market-level data on units, average selling prices, and values of the Alzheimer's disease therapeutics market share.
Prediction of the upcoming trends, drivers, and factors that challenge the growth of the Alzheimer's disease therapeutics market.
Alzheimer's disease therapeutics industry growth across North America, Europe, Asia, and Rest of World (ROW).
